Under the increasingly serious medical reform policy, how should pharmaceutical companies transform?

Pharmaceutical Network Market Analysis, according to public information, in recent years, pharmaceutical enterprises have become the main force eliminated by the market.analysis of the reasons behind it, mainly due to the impact of the policy environment.under the superposition of many new policies of medical reform, such as belt procurement, two-vote system, key monitoring catalogue, medical insurance control fee, and so on, the pharmaceutical industry structure has changed, and the "heavy sales, light research and development" model of pharmaceutical companies is constantly being restricted, and there is increasing pressure on profits. How should pharmaceutical companies transformthe health care reform policy? According to the author's understanding, since this year, there have been a number of well-known drugs filed for bankruptcy liquidation or bankruptcy., as on July 11, Yu Heng Pharmaceuticals announced that it had entered into bankruptcy reorganization proceedings, and the Shenzhen branch of China Securities Registration and Settlement Co., Ltd. has imposed a protective waiting freeze on the shares of Yuheng Group.", six pharmaceutical companies are also insolvent because they cannot operate.in short, in the environment, pharmaceutical business model transformation is imminent, then how to do? Innovation transformation with the 3rd batch of national pace is getting closer, the scale of collection expansion accelerated trend has been formed.at present, many places are restarting local drug collection, collection varieties from oral solid preparation swells to injections, from consistent over-evaluation varieties to unrated varieties, local and procurement alliances have been for high-value consumables sub-species began to explore the volume of procurement.overall, collection will be one of the core events of the year in the pharmaceutical sector for a long time., the industry believes that drugs, especially generics, will completely enter the low gross margin historical stage.in the environment, through the development of innovative drugs will become the future transformation of pharmaceutical enterprises.in fact, many pharmaceutical companies are becoming more aware of the need to develop innovative drugs and say they are accelerating the development of innovative drugs, which are indeed accelerating.take Yuandong Bio as an example, and for many years it has established a perfect research and development system in terms of high-end chemical drugs, with small molecule innovation drugs as the focus, and on biological medicine, from the framework of research and development organization, research and development equipment, research and development technology platform, research and development control system, external cooperative research and development mechanism, technical personnel training and incentive mechanism, etc.up to date, Yuandong Bio has successfully achieved the industrialization of 20 chemical preparation products and 14 chemical raw materials products, covering the key areas of anaesthetic analgesic, cardiovascular, anti-tumor, digestive, children's drug use and so on.in addition, from the perspective of the main body of innovative drug development, in addition to Yuandong Biological, China's emerging innovative pharmaceutical companies are emerging and growing rapidly, around a variety of strategies for product pipeline layout, so that China's innovative drug research and development has a hundred competing situation.but it is worth noting that China's innovative drugs and high-tech barriers generic drugs in the rapid development of the same time, but also face serious challenges. , for example, Chinese pharmaceutical companies are at risk of homogenization by focusing too much on treatments such as cancer and specific targets. , for example, PD-1, as a major battleground for innovative drugs, dozens of projects are in the clinical stage. the future, how to seek differentiation in target selection and molecular screening" or become the key to development. marketing transformation under the influence of the big environment, the drug company with gold sales model is being more and more limited. recently, the National Health and Care Commission Office issued "on the issuance of the 2020 medical industry style construction of the special action plan notice", it is clear that from July this year to the end of the year, will focus on the treatment of medical personnel to collect kickbacks, pharmaceutical companies illegal marketing and other acts. in this context, pharmaceutical companies need to reconstruct and adjust their marketing model as soon as possible, in order to better survive under the pressure of changing markets and policies. it is worth noting that pharmaceutical companies have two aspects of marketing needs: one is effective contact and effective feedback to target users, and the other is policy compliance, the marketing process can be transparent and traceable. the reality is that in the face of such a large demand for pharmaceutical marketing, the traditional pharmaceutical circulation and pharmaceutical marketing market is still quite scattered. to this, industry experts believe that in the pharmaceutical marketing from the offline to the line transformation becomes an inevitable trend, pharmaceutical companies can be more accurate through the Internet to reach the target users, affect the doctor group, drive sales. in the country to develop the Internet and the era of the current, in the face of the current digital media and marketing environment caused by many changes, China's pharmaceutical industry only as soon as possible to reconstruct the marketing awareness, in order to let the brand in the new era with consumer interaction, communication of new capabilities. at present, some pharmaceutical retail chain enterprises with reform thinking, pharmaceutical wholesale enterprises and pharmaceutical industry enterprises have begun to carry out the transformation of the Internet and pharmaceutical industry enterprises in the era, which is directly affecting and promoting the upgrading and reconstruction of traditional pharmaceutical enterprises, for the Chinese pharmaceutical industry in the transition period of marketing thinking reconstruction, pry more possibilities to break the situation. concluding the conclusion in general, in the current situation, pharmaceutical companies need to increase innovation ability, speed up the construction of low-cost and efficient online compliance academic marketing system, in order to achieve future preparations, ready to resist all kinds of huge industry risks!